Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Corvus Pharmaceuticals (CRVS) Restructuring Costs (2024 - 2026)

Corvus Pharmaceuticals' Restructuring Costs history spans 3 years, with the latest figure at $1.2 million for Q1 2026.

  • Quarterly Restructuring Costs rose 31.5% to $1.2 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $3.3 million through Mar 2026, up 7.11% year-over-year, with the annual reading at $3.0 million for FY2025, 4.13% down from the prior year.
  • Restructuring Costs came in at $1.2 million for Q1 2026, up from $561000.0 in the prior quarter.
  • In the past five years, Restructuring Costs ranged from a high of $1.2 million in Q1 2026 to a low of $551000.0 in Q2 2024.
  • The 3-year median for Restructuring Costs is $780000.0 (2024), against an average of $813000.0.
  • The largest YoY upside for Restructuring Costs was 53.9% in 2025 against a maximum downside of 28.08% in 2025.
  • Corvus Pharmaceuticals' Restructuring Costs stood at $780000.0 in 2024, then dropped by 28.08% to $561000.0 in 2025, then surged by 121.75% to $1.2 million in 2026.
  • Per Business Quant, the three most recent readings for CRVS's Restructuring Costs are $1.2 million (Q1 2026), $561000.0 (Q4 2025), and $617000.0 (Q3 2025).